Neuromyelitis optica and tactile and visual hallucinations in an elderly patient.
Although neuromyelitis optica initially described by Eugen Devic in 1897 was considered for many years as a variant of multiple sclerosis, clinical course, more aggressive from the start, progressive towards severe disability and poor visual prognosis, and a different response to treatment, clearly point to a different process. Anti-aquaporin 4 antibodies are a specific biomarker of the entity and, since their discovery, both the number of symptoms and the radiological data about the disease have progressively increased, and the concept of clinical spectrum of neuromyelitis optica has been defined.

 To our knowledge it is the first reported case of encephalopathy and neuromyelitis optica in elderly patient.
Geriatric Medicine Section, Hospital Universitario del Henares, Coslada, Madrid, Spain.
Patricia
P
López Pardo
Department of Geriatric Medicine, Hospital Central de la Cruz Roja , Madrid, Spain.
Concepción
C
Jiménez Rojas
Palliative Care Unit, Hospital Universitario de Móstoles, Móstoles , Madrid, Spain.
María
M
Moral Carretón
D000368:Aged; D051401:Aquaporin 4 / Q000276:immunology; D001323:Autoantibodies / Q000097:blood; D017809:Fatal Outcome; D005260:Female; D006212:Hallucinations / Q000209:etiology* / Q000503:physiopathology / Q000523:psychology; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D009471:Neuromyelitis Optica / Q000150:complications* / Q000503:physiopathology / Q000523:psychology / Q000628:therapy; D010956:Plasmapheresis; D055698:Touch Perception; D016896:Treatment Outcome; D014792:Visual Acuity; D014796:Visual Perception
C496030:AQP4 protein, human; D051401:Aquaporin 4; D001323:Autoantibodies; D007166:Immunosuppressive Agents